Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 4
2013 5
2014 9
2015 9
2016 11
2017 18
2018 13
2019 8
2020 12
2021 23
2022 16
2023 27
2024 25
2025 33

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Results by year

Filters applied: . Clear all
Page 1
Burkitt Lymphoma International Prognostic Index.
Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, Evens AM. Olszewski AJ, et al. Among authors: epperla n. J Clin Oncol. 2021 Apr 1;39(10):1129-1138. doi: 10.1200/JCO.20.03288. Epub 2021 Jan 27. J Clin Oncol. 2021. PMID: 33502927 Free PMC article.
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA. Neelapu SS, et al. Among authors: epperla n. Blood. 2024 Feb 8;143(6):496-506. doi: 10.1182/blood.2023021243. Blood. 2024. PMID: 37879047 Free PMC article.
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS. Scordo M, et al. Among authors: epperla n. JAMA Oncol. 2021 Jul 1;7(7):993-1003. doi: 10.1001/jamaoncol.2021.1074. JAMA Oncol. 2021. PMID: 33956047 Free PMC article.
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.
Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch R, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared J, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik A, Hill BT, Kamdar MK, Ortiz-Maldonado V, Martinez-Cibrian N, Shune L, Shadman M. Samples L, et al. Among authors: epperla n. Blood. 2025 Jun 5;145(23):2762-2767. doi: 10.1182/blood.2024026831. Blood. 2025. PMID: 39938007
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani M. Epperla N, et al. Transplant Cell Ther. 2023 Sep;29(9):548-555. doi: 10.1016/j.jtct.2023.06.012. Epub 2023 Jul 5. Transplant Cell Ther. 2023. PMID: 37419325 Free article.
Cardiovascular toxicities associated with bispecific T-cell engager therapy.
Sayed A, Munir M, Ghazi SM, Ferdousi M, Krishan S, Shaaban A, Habib A, Kola-Kehinde O, Ruz P, Khan S, Sharma S, Meara A, Mahmood S, Feldman S, Yang EH, Kim J, Epperla N, Addison D. Sayed A, et al. Among authors: epperla n. J Immunother Cancer. 2024 Feb 21;12(2):e008518. doi: 10.1136/jitc-2023-008518. J Immunother Cancer. 2024. PMID: 38388168 Free PMC article.
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies.
Umyarova E, Pei C, Pellegrino W, Zhao Q, Sharma N, Benson D, Cottini F, Bezerra E, Brammer J, Bumma N, Choe H, Denlinger N, Devarakonda S, Khan A, Penza S, Rosko A, Vasu S, Wall S, Alinari L, Baiocchi R, Bond DA, Christian B, Hanel W, Maddocks K, Reneau J, Sawalha Y, Habib A, Sigmund A, Voorhees TJ, de Lima M, Epperla N. Umyarova E, et al. Among authors: epperla n. J Hematol Oncol. 2025 Mar 18;18(1):30. doi: 10.1186/s13045-025-01676-4. J Hematol Oncol. 2025. PMID: 40098061 Free PMC article.
Editorial: Rising Stars in Hematologic Malignancies 2021.
Qian L, De Lima M, Mims AS, Epperla N. Qian L, et al. Among authors: epperla n. Front Oncol. 2022 Feb 25;12:858564. doi: 10.3389/fonc.2022.858564. eCollection 2022. Front Oncol. 2022. PMID: 35280758 Free PMC article. No abstract available.
194 results